Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
'Adaptive' approaches to bringing drugs to market have been widely discussed in recent years. Here, we describe the evolution of the adaptive approach and of concepts developed by ADAPT SMART, a multi-stakeholder consortium funded by the European Innovative Medicines Initiative.
A panel of independent experts voted narrowly in favour of continuing to require cardiovascular outcomes data for new diabetes drugs, but urged relaxation and simplification of the safety assessment.
Since 2015, the Chinese government has introduced numerous reforms with the aim of establishing a more scientific and efficient drug regulatory system, which are highlighted here.
Mitochondrial dysfunction contributes to many common disorders, and therapeutic strategies aimed at restoring mitochondrial function are now emerging, with a small number of agents now in clinical trials. Here, Murphy and Hartley assess therapeutic approaches and challenges in targeting mitochondria and highlight examples of promising indications.
Tumour-associated macrophages (TAMs) promote cancer initiation and malignant progression. This Review evaluates current strategies to target TAMs, exploring their toxicity and compensatory mechanisms, and proposes novel strategies in light of new findings regarding macrophage biology and their mechanism of action.
The connexin family of channel-forming proteins is critical for cellular communication, being involved in both health and disease. Here, Laird and Lampe assess the potential of connexins as therapeutic targets in acquired and inherited diseases, as well as wound repair, highlighting agents currently in development and the associated clinical challenges.